Tofranil Related Published Studies
Well-designed clinical trials related to Tofranil (Imipramine)
Treatment of Panic Disorder with Agoraphobia: Randomized Placebo-Controlled Trial of Four Psychosocial Treatments Combined with Imipramine or Placebo. [2008.06.13]
Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. [2008.01]
Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. [2008]
The effects of imipramine on P50 suppression, prepulse inhibition and habituation of the startle response in humans. [2007.12]
Antidepressant Therapy (Imipramine and Citalopram) for Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Trial. [2007.05.15]
Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine. [2006.04]
Imipramine is effective in preventing relapse in electroconvulsive therapy-responsive depressed inpatients with prior pharmacotherapy treatment failure: a randomized, placebo-controlled trial. [2006.02]
[Comparison of the effectiveness of two treatment strategies in inpatients with a depressive disorder. A double-blind study of imipramine followed by lithium addition versus fluvoxamine followed by lithium addition] [2006]
Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed? [2005.09]
Comparison of effects of treatment of primary nocturnal enuresis with oxybutynin plus desmopressin, desmopressin alone or imipramine alone: a randomized controlled clinical trial. [2005.09]
Well-designed clinical trials possibly related to Tofranil (Imipramine)
Relapse following combined treatment discontinuation in a placebo-controlled trial for panic disorder. [2008.07]
Reduced Stress-Sensitivity or Increased Reward Experience: The Psychological Mechanism of Response to Antidepressant Medication. [2008.05.21]
A simple validated scale to measure urgency. [2008.03]
Health-related quality of life and its predictive role for analgesic effect in patients with painful polyneuropathy. [2007.07]
Cost-efficacy of individual and combined treatments for panic disorder. [2007.07]
Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status. [2007.06]
Group composition and group therapy for complicated grief. [2007.02]
Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response. [2006.09]
Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorder. [2005.06]
Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. [2005.06]
Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. [2005.06]
Trospium chloride for the treatment of overactive bladder with urge incontinence. [2005.05]
A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. [2005.05]
Other research related to Tofranil (Imipramine)
Treating thermally injured children suffering symptoms of acute stress with imipramine and fluoxetine: a randomized, double-blind study. [2008.11]
Combination therapy of imipramine and melatonin: additive antidepressant effect in mouse forced swimming test. [2008.09.04]
Treating thermally injured children suffering symptoms of acute stress with imipramine and fluoxetine: A randomized, double-blind study. [2008.07.31]
Effects of age on susceptibility to the induction of depressive behavior and imipramine in rats. [2008.07]
Effects of imipramine hydrochloride on the EEG of children with Attention-Deficit/Hyperactivity Disorder who are non-responsive to stimulants. [2008.06]
Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. [2008.06]
Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors? [2008.05]
Efficacy of Imipramine in Psychotic Versus Nonpsychotic Depression. [2008.04]
Effects of imipramine hydrochloride on the EEG of children with Attention-Deficit/Hyperactivity Disorder who are non-responsive to stimulants. [2008.02.01]
Tolterodine and imipramine in refractory enuresis; a placebo-controlled crossover study. [2008.02]
Cortisol level in men with major depressive disorder treated with fluoxetine or imipramine. [2008.01]
Imipramine reverses the depressive symptoms in sepsis survivor rats. [2007.12]
Tolterodine and imipramine in refractory enuresis; a placebo-controlled crossover study. [2007.11.15]
Evaluation of ketamine, nimodipine, gabapentin and imipramine in partial sciatic nerve transection model of neuropathic pain in rat: an experimental study. [2007.09]
Repeated co-treatment with imipramine and amantadine induces hippocampal brain-derived neurotrophic factor gene expression in rats. [2007.06]
Effects of acute and chronic antidepressant treatments on memory performance: a comparison between paroxetine and imipramine. [2007.04]
Influence of zinc supplementation on imipramine effect in a chronic unpredictable stress (CUS) model in rats. [2007.01]
Increased hippocampal nitric oxide synthase activity and stress responsiveness after imipramine discontinuation: role of 5HT 2A/C-receptors. [2006.09]
Immobility stress induces depression-like behavior in the forced swim test in mice: effect of magnesium and imipramine. [2006.09]
Cell proliferation is influenced by bulbectomy and normalized by imipramine treatment in a region-specific manner. [2006.06]
Effect of amantadine and imipramine on immunological parameters of rats subjected to a forced swimming test. [2006.06]
Neonatal citalopram exposure produces lasting changes in behavior which are reversed by adult imipramine treatment. [2006.02.27]
Effect of imipramine on the behavior and cerebral 5-HT1A serotonin receptors in mice genetically predisposed to catalepsy. [2006.01]
Imipramine-induced facial pigmentation: case report and literature review. [2005.12]
Repeated administration of citalopram and imipramine alters the responsiveness of rat hippocampal circuitry to the activation of 5-HT7 receptors. [2005.11.07]
Urodynamics-based evidence for the beneficial effect of imipramine on valve bladders in children. [2005.10]
An autopsy case of imipramine poisoning. [2005.09]
Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s. [2005.06.15]
Subchronic treatment with imipramine ameliorates the decreased number in neuropeptide Y-positive cells in the hippocampus of learned helplessness rats. [2005.06.07]
Metabotropic glutamate receptors and neuroadaptation to antidepressants: imipramine-induced down-regulation of beta-adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands. [2005.06]
Effects of intraperitoneally injected lithium, imipramine and diazepam on nitrate levels in rat amygdala. [2005.06]
Effect of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat. [2005.03]
QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. [2005.03]
Transdermal delivery of imipramine hydrochloride: development and evaluation (in vitro and in vivo) of reservoir gel formulation. [2005.03]
Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine. [2005.02.01]
Single and multiple dose pharmacokinetic evaluation of a transdermal delivery system of imipramine hydrochloride. [2005]
Other possibly related research studies
A comparison of medication side effect reports by panic disorder patients with and without concomitant cognitive behavior therapy. [2007.02]
A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. [2006.10]
Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats. [2006.12.28]
Health-related quality of life and its predictive role for analgesic effect in patients with painful polyneuropathy. [2006.10.16]
Efficacy of tricyclic antidepressant is associated with beta2-adrenoceptor genotype in patients with interstitial cystitis. [2006.08]
Therapeutic tricyclic antidepressant drug monitoring in younger and older depressive patients. [2006.07]
Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. [2006.11]
Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. [2006.09]
Overactive bladder syndrome: considerations in pharmacotherapy and new perspectives. [2006]
Monoamine uptake inhibitors block alpha7-nAChR-mediated cerebral nitrergic neurogenic vasodilation. [2006.07]
SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? [2006.09]
Delusion of oral parasitosis in a patient with major depressive disorder. [2006.01]
Induction of neuroserpin expression in rat frontal cortex after chronic antidepressant treatment and electroconvulsive treatment. [2006.02]
Antidepressant-like activity of n-hexane extract of nutmeg (Myristica fragrans) seeds in mice. [2006.03]
The evaluation and treatment of therapy-resistant enuresis: a review. [2006]
Life stress and the long-term treatment course of recurrent depression: III. Nonsevere life events predict recurrence for medicated patients over 3 years. [2006.02]
G(olf) protein levels in rat striatum are increased by chronic antidepressant administration and decreased by olfactory bulbectomy. [2006.06.27]
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. [2006.04]
Reboxetine in therapy-resistant enuresis: results and pathogenetic implications. [2006]
Psychopathology of panic attacks in panic disorder. [2006.05]
Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels. [2006.01.11]
Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. [2005.12]
Zinc and depression. An update. [2005.11]
Effects of forced swimming stress on rat brain function. [2005.11]
Eye-wiping test: a sensitive animal model for acute trigeminal pain studies. [2005.12]
Early treatment of acute stress disorder in children with major burn injury. [2005.11]
Differential gender-related vulnerability to depression induction and converging antidepressant responses in rats. [2006.02]
Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. [2006.05.01]
Combination therapy with alarm and drugs for monosymptomatic nocturnal enuresis not superior to alarm monotherapy. [2005.09]
Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. [2005.07]
The effect of antinociceptive drugs tested at different times after nerve injury in rats. [2005.07]
Overactive bladder syndrome: considerations in pharmacotherapy and new perspectives. [2005.06.01]
Announced rewards counteract the impairment of anticipatory behaviour in socially stressed rats. [2005.06.20]
Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains. [2005.06.03]
Pain predicts longer time to remission during treatment of recurrent depression. [2005.05]
The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. [2005.03]
SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. [2005.08]
The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder. [2005.03]
Overactive bladder: evaluation and management in primary care. [2005.02]
Monoaminergic drugs and directly observable signs of LAAM withdrawal in rhesus monkeys. [2005.02]
Antidepressant effect of Chaihu-Shugan-San extract and its constituents in rat models of depression. [2005.01.28]
Role of the orbital cortex and of the serotonergic system in a rat model of obsessive compulsive disorder. [2005]
|
